Edition:
India

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

57.40USD
15 Dec 2017
Change (% chg)

$1.72 (+3.09%)
Prev Close
$55.68
Open
$55.78
Day's High
$57.87
Day's Low
$55.78
Volume
568,366
Avg. Vol
128,575
52-wk High
$97.14
52-wk Low
$45.05

Latest Key Developments (Source: Significant Developments)

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT.EAGLE PHARMACEUTICALS- ANTICIPATES COMPLETION OF FULVESTRANT STUDY WITHIN TWELVE MONTHS, AND AN EXPECTED NDA FILING IN Q4 OF 2018.  Full Article

Eagle Pharmaceuticals Q3 earnings per share $0.98
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals Inc reports third quarter 2017 results.Q3 adjusted non-GAAP earnings per share $1.22.Q3 earnings per share $0.98.Q3 revenue $63 million versus I/B/E/S view $51.9 million.Q3 earnings per share view $0.80 -- Thomson Reuters I/B/E/S.Expect full year 2017 research and development expense will be consistent with upper end of $31-$35 million range​.Plan to begin dosing patients in Fulvestrant study in a few weeks and expect to file an NDA in Q4 of 2018​.Expect full year 2017 SG&A expense to be in range of $67 million - $70 million, slightly higher than previous guidance​.Will continue purchasing up to an additional $100 million shares under current share repurchase plan​.On PEMFEXY, says "hope to find a way to market" as soon as possible, once co's litigation with Eli Lilly is resolved​.  Full Article

EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY
Saturday, 28 Oct 2017 

Oct 27 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY (PEMETREXED INJECTION) READY-TO-DILUTE.EAGLE PHARMACEUTICALS INC - ‍FDA HAS GRANTED TENTATIVE APPROVAL FOR COMPANY'S PEMFEXY​.  Full Article

Eagle Pharmaceuticals reports positive results from animal study supporting efficacy of RYANODEX for exertional heat stroke
Tuesday, 13 Dec 2016 

Eagle Pharmaceuticals Inc : Eagle Pharmaceuticals inc - we anticipate completing NDA filing as soon as possible for RYANODEX . Eagle Pharmaceuticals reports positive results from pivotal animal study supporting the efficacy of RYANODEX for exertional heat stroke . Robust and clinically meaningful treatment difference in favor of RYANODEX was statistically significant . Eagle pharmaceuticals - eagle could be first to market with a potentially life-saving treatment for EHS, if approved by FDA, as early as mid-2017 .Eagle Pharmaceuticals - clinical and nonclinical components of development program provide adequate safety, efficacy data to complete our NDA submission.  Full Article

Eagle Pharma Q2 earnings $0.80/shr
Tuesday, 9 Aug 2016 

Eagle Pharmaceuticals Inc : Reports second quarter 2016 results . Announces $75 million share repurchase program . Changes in shareholders' stock holdings may trigger a "technical change of control" . Should co be required to amortize nol, there will be a cash impact of approximately $10 mln incurred over next few quarters . Changes in structure of co's shareholders' stock holdings may trigger how co "utilizes accumulated net operating losses" . Q2 shr view $0.71 -- thomson reuters i/b/e/s . Q2 revenue $40.9 mln vs i/b/e/s view $40.8 mln .Q2 shr $0.80.  Full Article

Eagle pharmaceuticals updates on FDA meeting for Ryanodex
Tuesday, 9 Aug 2016 

Eagle Pharmaceuticals Inc : Eagle Pharmaceuticals reports positive outcome from fda meeting for Ryanodex for exertional heat stroke NDA submission . Hajj study results sufficient for human data in filing . Eagle purchases royalty rights to Ryanodex portfolio . Purchases royalty rights to Ryanodex portfolio . Reduced future Ryanodex royalty obligations to licensing partner from 15% to 3% of net sales in exchange for $15 million in cash .Expect requesting priority review of nda for Ryanodex and, if granted by FDA, to market treatment for ehs as early as next year.  Full Article

Hudson Executive reports 6.1 pct stake in Eagle Pharmaceuticals
Tuesday, 28 Jun 2016 

Eagle Pharmaceuticals Inc :Hudson Executive Capital Lp reports 6.1 percent stake in Eagle Pharmaceuticals Inc as of June 15 - SEC filing.  Full Article

Eagle Pharmaceuticals Q1 loss per share $0.06
Monday, 9 May 2016 

Eagle Pharmaceuticals Inc : Qtrly loss per share $0.06 . Q1 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S . Eagle Pharmaceuticals, Inc. Reports first quarter 2016 results; Bendeka achieves 71% total market share . Q1 revenue $29.6 million versus $36.3 million .Q1 revenue view $14.3 million -- Thomson Reuters I/B/E/S.  Full Article

Eagle Pharmaceuticals Inc receives sixth patent for Bendamustine
Tuesday, 23 Feb 2016 

Eagle Pharmaceuticals Inc:Says United States Patent and Trademark Office has granted U.S. Patent No. 9,265,831, which pertains to liquid bendamustine hydrochloride formulations.  Full Article

Eagle Pharmaceuticals Inc and AMRI agree to jointly develop parenteral drug products
Monday, 11 Jan 2016 

Eagle Pharmaceuticals Inc:Eagle Pharmaceuticals and AMI announce agreement to jointly develop, manufacture and commercialize parenteral drug products.Says Eagle will be responsible for U.S. commercial distribution of all approved products, once approved by the FDA.AMI will supply products to Eagle pursuant to commercial supply agreement,receive payments based on eagle's sales of products.AMI will develop, initially provide CGMP manufacturing, analytical support for registration of new product candidates.  Full Article